[ad_1] Regeneron Pharmaceuticals (NASDAQ: REGN) is still frequently framed through one question: how much pressure will EYLEA face from competition, biosimilars, and the transition to EYLEA HD? That question matters, but it no longer captures the whole investment story. Regeneron…
[ad_1] Image source: Getty Images Global markets opened on shaky ground this week following renewed tensions in the Middle East. While US markets were hit hardest, the FTSE 100 hasn’t escaped unscathed. Crude oil jumped 2.78% to $93 a barrel…
[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence Old Dominion Freight Line plunged 5.2% on Wednesday despite a trio of analyst upgrades that lifted price targets an average of 13.8%. The trucking giant’s shares fell to $235.85 on volume of 1.1M…
[ad_1] Image source: Getty Images FTSE 100 value stocks have been left behind as investors chase US growth and AI winners. But with valuations now compressed across several large-cap names, the question is whether the market is being cautious —…
[ad_1] Why Royal Caribbean has a yield-and-destination engine bigger than a simple cruise rebound trade Royal Caribbean is still often framed as a cyclical leisure stock that rises and falls with vacation demand. That misses how much of the story…
[ad_1] Image source: Getty Images If you rewind to five years ago, Lloyds (LSE: LLOY) shares closed the day on 11 June 2021 at a lowly 48.4p each. That means 10,000 of them could have been bought with £4,840. As…
[ad_1] Why Ares is more than a simple private-markets beta trade Ares Management (ARES) is often treated as a public-market proxy for enthusiasm around alternative assets. That view is too blunt. The better way to read Ares is as a…
[ad_1] Image source: Getty Images A Self-Invested Personal Pension (SIPP) is a long-term investment vehicle, given that many people hold the pension wrapper for decades before drawing out a single pound. That means it can be a natural fit for…
[ad_1] Why Bristol Myers is more than a patent-cliff story Bristol Myers Squibb is often reduced to a familiar big-pharma problem: legacy blockbusters lose exclusivity, revenue steps down, and the market waits to see whether the pipeline can plug the…
[ad_1] Image source: Getty Images UK investors have been piling into Broadcom (NASDAQ: AVGO) shares since they crashed (more than 20%) after its earnings report. Last week, they were among the most bought shares on AJ Bell. Is this a…